Marta S.
- Country
- Spain
- Department
- Medical Oncology
Research Overview
- Evaluation of Administration Route Preference for Nivolumab and Relatlimab in Melanoma Patients: Subcutaneous Versus Intravenous Delivery
- Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Ficlatuzumab and Cetuximab in Recurrent or Metastatic HPV-Negative Head and Neck Squamous Cell Carcinoma
- Efficacy and Safety Evaluation of Enfortumab Vedotin and Pembrolizumab in Advanced Melanoma: A Phase II, Open-Label, Multicenter Study
Data & Insights
Has run more than one trial at 28 of 137 partner sites.
Specializations
Head and Neck Cancer Research
Specializes in investigating novel therapeutic approaches for head and neck squamous cell carcinoma (HNSCC), with particular focus on immunotherapy combinations and treatment strategies for both localized and metastatic disease.
- PD-L1 positive recurrent/metastatic HNSCC
- Locally advanced unresected head and neck cancer
- HPV-negative head and neck cancer
Explores treatment modalities including chemoradiation combinations and targeted therapies.
Melanoma Treatment
Conducts research in advanced melanoma therapeutics, focusing on innovative combination approaches and novel immunotherapy agents for various disease stages.
- Advanced unresectable/metastatic melanoma
- Stage III and IV melanoma
- Post-surgical melanoma treatment
Investigates both established and emerging immunotherapy combinations for optimal treatment outcomes.
Immunotherapy Innovation
Leads investigations into novel immunotherapy combinations and treatment strategies, particularly focusing on immune checkpoint inhibitors and their combinations.
- Checkpoint inhibitor combinations
- Biosimilar development
- First-line immunotherapy treatments
Evaluates efficacy of various immunotherapy agents in different cancer types.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.